Comparisons | No of studies (patients) | Percentage of low/negative BRCA1(%) | ORR: low/negative vs high/postive (%) | Overall OR/HR (95% CI) fixed and random | Heterogeneity test | P for publication bias |
---|---|---|---|---|---|---|
Platinum-based | Â | Â | Â | Â | Â | Â |
ORR overall | 16(1330) | 44.4 | 48.9 vs 38.1 | 1.70 (1.32, 2.18), 1.80(1.26,2.55) | I2 = 44.7%,P = 0.03 | 0.15 |
Method | Â | Â | Â | Â | Â | Â |
IHC | 13(1066) | 44.5 | 50.7 vs 39.0 | 1.54(1.17,2.00), 1.59(1.07,2.36) | I2 = 44.8%,P = 0.03 | 0.41 |
RT-PCR | 4(264) | 44.3 | 43.7 vs 25 | 2.91 (1.55, 3.83), 2.91(1.55,5.47) | I2 = 0.0%, P = 0.52 | 0.76 |
Origin | Â | Â | Â | Â | Â | Â |
East-Asian | 14(1133) | 45.4 | 51.0 vs 36.0 | 1.68(1.30,2.19), 1.79(1.24,2.60) | I2 = 39.9%,P = 0.04 | 0.10 |
Caucasian | 3(197) | 38.6 | 39.8 vs 33.4 | 1.79 (0.84, 3.83), 1.77(0.50,6.28) | I2 = 63.6%,P = 0.06 | 0.90 |
OS | 8(733) | - | - | 1.58(1.27,1.97), 1.65(1.19,2.89) | I2 = 48.4%,P = 0.03 | 0.13 |
EFS | 6(599) | - | - | 1.62(1.28,2.05), 1.60(1.07,2.39) | I2 = 54.5%,P = 0.02 | 0.88 |
Toxal-based | Â | Â | Â | Â | Â | Â |
ORR overall | 4(376) | 41.3 | 26.0 vs 46.1 | 0.41(0.26,0.64), 0.41(0.27,0.64) | I2 = 0.0%, P = 0.61 | 0.84 |